Kuala lumpur: Eyexora announced today its launch as the first company founded to accelerate innovation in ophthalmology using a hub-and-spoke model. The company is building a global portfolio starting with collaborations in Singapore and Europe, with its initial assets in-licensed from the Singapore Eye Research Institute (SERI).

According to BERNAMA News Agency, Eyexora's seed financing was led by life sciences investor ClavystBio, with participation from leading ophthalmology experts. The company's mission is to advance a diversified portfolio of anterior and posterior segment therapeutics, as well as ophthalmic devices, in a $50 billion global market serving more than two billion patients.